Noboru Yamamoto, Takafumi Koyama, Jun Sato, Tatsuya Yoshida, Kazuki Sudo, Satoru Iwasa, Shunsuke Kondo, Kan Yonemori, Atsuko Kawasaki, Kyoko Satake, et al. Correction to: Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors. Cancer chemotherapy and pharmacology. 2024. 94. 3. 491-491
Pierre Peterlin, Esma Saada-Bouzid, Mor Moskovitz, Arnaud Pigneux, Junichiro Yuda, Mahipal Sinnollareddy, William R Henner, Diana Chen, Kevin J Freise, Rachel S Leibman, et al. First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC. Expert review of anticancer therapy. 2024. 24. 9. 893-904
Takafumi Koyama, Kan Yonemori, Toshio Shimizu, Jun Sato, Shunsuke Kondo, Kazuki Sudo, Tatsuya Yoshida, Yuki Katsuya, Tatsuki Imaizumi, Masashi Enomoto, et al. Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors. Cancer research communications. 2024. 4. 9. 2349-2358
Toshiaki Takakura, Hiroaki Akamatsu, Atsushi Washioka, Eriko Murakami, Ryota Shibaki, Toshio Shimizu, Yasuhiro Koh, Nobuyuki Yamamoto. Unsuccessful rechallenge with nivolumab in a patient with advanced non-small cell lung cancer who had a 6-year complete response and treatment-free period: Case report. Respirology case reports. 2024. 12. 9. e01401
Toshiaki Takakura, Toshio Shimizu, Nobuyuki Yamamoto. Antibody-drug conjugates in solid tumors; new strategy for cancer therapy. Japanese journal of clinical oncology. 2024. 54. 8. 837-846
A first-in-Asian phase I dose escalation study to evaluate the safety and pharmacokinetics of VS-6063 (defactinib), a focal adhesion kinase inhibitor in subjects with non-hematologic malignancies
(The 73rd Annual Meeting of the Japanese Cancer Association (JCA) 2014)
Phase I study of YM155, selective survivin suppressant plus elrotnib in patients with EGFR-mutant advanced non-small-cell lung cancer (NSCLC)
(The 12th Annual Meeting of Japanese Society of Medical Oncology 2014)
Completed Phase I Trial of TLC388
(The 3rd Japan-Taiwan Phase I Oncology Conference (JTOPIC), Taipei, Taiwan 2014)
Infrastructural capability of investigator-initiated trials involving unapproved investigational drugs in Japan
(The 11th Annual Meeting of Japanese Society of Medical Oncology 2013)
2003 - 2007 Kinki University Graduate School Medical Oncology
1993 - 1999 Kinki University Faculty of Medicine Faculty of Medicine
Professional career (1)：
博士(医学) (近畿大学)
Work history (8)：
2024/11 - 現在 Kansai Medical University Department of New Experimental Therapeutics Professor
2022/04 - 2024/10 Wakayama Medical University Associate Professor
2016/04 - 2022/03 National Cancer Center Hospital of Japan Department of Experimental Therapeutics Head of Physician (Early Phase 1 Drug Development Service)
2012/04 - 2016/03 Kindai University Faculty of Medicine Department of Medical Oncology Associate Professor
2010/01 - 2012/03 START (South Texas Accelerated Research Therapeutics) Phase I Center Clinical Fellow
2010/01 - 2011/12 The Univerisity of Texas at Austin College of Pharmacy Visiting Researcher
2005/07 - 2009/12 Kindai University Faculty of Medicine Department of Medical Oncology Assistant Professor
2002/06 - 2005/06 National Cancer Center Hospital Internal Medicine (Phase I Drug Development) Clinical Resident
2020/04 - 現在 Asia Pacific Oncology Drug Development Consortium (APODDC) Executive Committee
2017/04 - 現在 The Consortium on Harmonization of Institutional Requirements for Clinical Research (CHAIR) Joint Scientific Committee Review Member for Phase 1 trials in Hong Kong, HKSAR IRB Member / Joint Scientific Committee Review Member for Phase 1 trials in Hong Kong, HKSAR
2013/04 - 現在 日本臨床腫瘍学会 学術企画委員
2012/04 - 現在 日本臨床腫瘍学会 協議員
Awards (2)：
2019/10 - Chinese Society of Clinical Oncology (CSCO) CSCO 2019 Travel Grant Award 受賞
2011/06 - ASCO ASCO 2011 Merit Award The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in first-in-human phase 1 study
Association Membership(s) (8)：
日本製薬医学会
, THE JAPANESE SOCIETY OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
, THE JAPAN LUNG CANCER SOCIETY
, JSMO(日本臨床腫瘍学会)
, THE JAPANESE SOCIETY OF INTERNAL MEDICINE
, ASCO(American Society of Clinical Oncology)
, ESMO (European Society of Medical Oncology)
, AACR (American Association of Cancer Research)
